<span item_type="fundamental" item_id="dc52edeee32f53e5dcb89f12532d02ab" counter_id="ST/US/ACUT" env="prod"></span><span item_type="announcement" item_id="549367267092991489" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.02.</p><p>EBIT: As of FY2025 Q2, the actual value is USD -401.4 K.</p><p></p><h3>Financial Metrics by Segment</h3><h4>Segment Revenue</h4><ul><li>No revenue reported for the three and six months ended June 30, 2025 and 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1850767/000164117225023786/form10-q.htm"></span></li></ul><h4>Operational Metrics</h4><ul><li><strong>Net Loss</strong>:<ul><li>Three months ended June 30, 2025: - $401,403</li><li>Three months ended June 30, 2024: - $278,225</li><li>Six months ended June 30, 2025: - $841,811</li><li>Six months ended June 30, 2024: - $804,827</li></ul></li><li><strong>Research and Development Expenses</strong>:<ul><li>Three months ended June 30, 2025: $60,204</li><li>Three months ended June 30, 2024: $41,746</li><li>Six months ended June 30, 2025: $88,550</li><li>Six months ended June 30, 2024: $64,943</li></ul></li><li><strong>General and Administrative Expenses</strong>:<ul><li>Three months ended June 30, 2025: $341,199</li><li>Three months ended June 30, 2024: $236,479</li><li>Six months ended June 30, 2025: $753,261</li><li>Six months ended June 30, 2024: $739,884</li></ul></li></ul><h4>Cash Flow</h4><ul><li><strong>Operating Cash Flow</strong>:<ul><li>Six months ended June 30, 2025: - $268,615</li><li>Six months ended June 30, 2024: - $446,533</li></ul></li><li><strong>Financing Cash Flow</strong>:<ul><li>Six months ended June 30, 2025: $294,910</li><li>Six months ended June 30, 2024: $471,124</li></ul></li><li><strong>Cash at End of Period</strong>:<ul><li>June 30, 2025: $31,341</li><li>June 30, 2024: $46,072</li></ul></li></ul><h4>Unique Metrics</h4><ul><li><strong>Accumulated Deficit</strong>:<ul><li>June 30, 2025: $8,868,858</li><li>June 30, 2024: $7,326,772</li></ul></li><li><strong>Working Capital Deficit</strong>:<ul><li>June 30, 2025: $2,534,687</li></ul></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><ul><li><strong>MSC Test</strong>: Plan to launch for clinical use in early 2026. The test is designed to help determine whether lung nodules identified by LDCT screening are benign or malignant.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1850767/000164117225023786/form10-q.htm"></span></li><li><strong>StemPrintER</strong>: Focus on commercialization for patients with early-stage breast cancer. The test predicts the risk of distant recurrence in luminal breast cancer patients.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1850767/000164117225023786/form10-q.htm"></span></li></ul><h4>Non-Core Business</h4><ul><li><strong>Additional Testing</strong>: Plan to offer additional “commodity” testing (e.g., next generation sequencing) to create value for customers and provide additional revenue opportunities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1850767/000164117225023786/form10-q.htm"></span></li></ul><h4>Priority</h4><ul><li><strong>Commercialization Milestones</strong>: Achieve key milestones such as identifying or building a laboratory for processing, testing, and reporting MSC results, transferring MSC to a commercial laboratory in the US, and obtaining CLIA certification.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1850767/000164117225023786/form10-q.htm"></span></li></ul>

AccuStem Sciences, Inc. | 10-Q: FY2025 Q2 EPS: USD -0.02